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TUBERCULOSIS INCREASES THE SURVIVAL OF  
B-CELLS THROUGH THE BAFF SYSTEM MOLECULES IN HIV PATIENTS. 
PHOEBE OHEMAH ASANTE 
ABSTRACT 
Since the human immunodeficiency virus (HIV) epidemic in the 1980s, great 
strides have been made regarding drug therapeutics, which has slowed the progression of 
HIV to AIDS and decreased the mortality rates in HIV patient populations. Other 
prevention interventions, such as pre-exposure prophylaxis (PrEP), have also contributed 
immensely to reducing HIV infections. However, today in many parts of the world, 
especially in sub-Saharan Africa, HIV is still prevalent. This demonstrates the need to 
focus on more long-term preventative interventions, such as vaccines. In order to do this, 
more research has to be conducted on the B cell adaptive immune response to HIV. This 
thesis research explores how the opportunistic disease tuberculosis, which is present in 
many HIV-positive patients, affects B cell survival in these HIV patients. Our methods 
section consists of CD14+ cell isolation and MDM culture experiments that we 
performed and subsequent planned experiments that we are yet to complete. These 
experiments include infecting MDM cultures with a double pseudotyped VSVg-NL43 
HIV. We will also expose the MDMs to the TB antigen, lipomannan (LM), to represent 
HIV/TB co-infection in vitro. LM is a toll-like receptor 2 (TLR2) agonist. The MDM 
cultures will enable us to measure the amount of BAFF and APRIL mRNA produced in 
the HIV, HIV/LM, and LM MDM cultures using RT-PCR. Using a growth curve, we will 
observe BAFF and APRIL's effects on the survival of B cells in the different MDM 
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cultures. We hypothesize that the TB antigen will increase B-cell survival through the 
BAFF system molecules in HIV patients. The results of our research will provide insights 
on the role TB plays in enhancing the humoral immune response in HIV-1 patients, 
paving the way for further research on understanding the mechanism responsible for this 
and consequently creating vaccine and vaccine adjuvant opportunities.  
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Human Immunodeficiency Virus (HIV) is one of the most common infectious 
diseases globally, with its highest prevalence in the Americas, Africa, and South-East 
Asia.1 As a result, HIV is considered a global health crisis. As of 2019, it is estimated that 
about 37.9 million people globally are living with HIV.1 HIV-1 is the most common type 
of HIV, and HIV-2 is primarily endemic to West Africa. HIV-1 compared to HIV-2, is 
more virulent and more transmissible, highlighting the importance and urgency in taking 
steps to find drug therapeutics for HIV-1.2 As a result, HIV-1 will be the primary focus of 
this thesis.  
HIV-1 is a retrovirus that belongs to the Lentivirus genus of the Retroviridae 
family. The virus has a double-stranded RNA and is transmissible not only between 
humans but also between non-human primates and humans.2 HIV-1 has an envelope made 
up of the envelope glycoprotein Gp160, and its core is surrounded by a capsid protein that 
contains viral genomic RNA and replication enzymes. The enzymes present in the core of 
HIV are reverse transcriptase (RT), integrase, and protease (Figure 1).3 HIV-1 targets 
primarily CD4+ T-helper lymphocytes (Th1) and sometimes macrophages using Gp160. 
These glycoproteins facilitate the entry of HIV into the host’s cell.3 Gp160 binds to the 
CD4 surface receptor on T-helper Lymphocytes and the chemokine receptor, CCR5, on 
macrophages and CD4+ T-helper lymphocytes.3 After the Gp160 facilitated entry, the 
membranes of both the host cell and the HIV-1 virus fuses, expelling viral RNA into the 
cytoplasm of the host cell. While in the host cell, reverse transcriptase synthesizes proviral 
DNA from viral RNA, and integrase integrates proviral DNA into the genome of the host’s 
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cell. The host cell’s transcription and translation machinery then transcribes proviral DNA 
to RNA and then HIV RNA into HIV proteins respectively. The proteins are cleaved by 
HIV-1 proteases, and the newly formed viral product buds of the cell through the host cell 
membrane, consequently spreading the infection to other cells (Figure 2).  
The hallmark of an HIV infection is the depletion of CD4+ T-lymphocytes. This 
decrease in CD4 count compromises the adaptive immune system, and as a result, over 
time, the HIV infection progresses into Acquired Immunodeficiency Syndrome (AIDS) if 
left untreated. The 6-year survival probabilities from the onset of AIDS to AIDS-related 
deaths in untreated patients are approximately 18%, which is relatively low compared to 
the approximately 76% survival probability of patients, adherent to highly active 
antiretroviral therapy (HAART).4 In 2019, about 67% of all adults living with HIV had 
access to antiretroviral therapy.5 HAARTs are either prescribed individually or in 
combination with others. The most common HAARTs prescribed today are nucleoside 
reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), integrase inhibitors (II), and protease inhibitors (PIs). These inhibitors target 
the HIV enzymes, reverse transcriptase, and proteases, respectively.3  
Furthermore, HIV purging these T-helper Lymphocytes and the consequence of 
immune suppression, makes HIV patients susceptible to opportunistic infections such as 
tuberculosis (TB). Globally, about of 13% HIV patients have tuberculosis. Additionally, 
HIV patients are approximately 26 times more likely to develop TB than HIV-negative 
patients.2 TB is an infectious disease caused by inhalation of the pathogen Mycobacterium 
tuberculosis (Mtb) droplets from TB-positive individuals. Mtb, the causative agent of TB, 
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has a hydrophobic cell envelope comprised of a capsule, an intermembrane, a 
peptidoglycan layer, an arabinogalactan layer, and an inner plasmid. The outer membrane, 
also known as the mycomembrane, is composed of mycolic acids and extractible lipids.6 
The cell envelope also contains lipoglycans such as lipomannan (LM) and 
lipoarabinomannan (LAM).6 When in the lungs, Mtb primarily targets alveolar 
macrophage cells, preventing them from carrying out phagocytosis and other innate 
immune responses. This leads to an increased spread of TB infection. Mtb interacts with 
pattern recognition receptors (PRRs) on phagocytic cells like macrophages. These cells 
recognize pathogen-associated molecular patterns (PAMPS) on the surface of Mtb. PRRs 
such as Toll-like Receptors (TLRs) facilitate phagocytosis and also trigger the innate 
immune response. TLR2s and TLR4s, a subset of TLRs, recognize structures LM and LPS, 
respectively, on the Mtb envelope, .6 
As seen by the improvement in AIDS-related mortality, the introduction of HAART 
as a treatment option, has saved many lives and continues to save many lives today. This 
is because HAART reduces viral loads and transmission rates. However, this treatment 
option is not infallible as resistant strains can arise. Moreover, the toxicity of these 
inhibitors can bring about other complications.3 This, therefore, highlights the need to find 
alternative therapeutics for HIV.  
Recent evidence shows a significant increase in immunoglobulin G (IgG) 
plasmablasts and BCG specific IgG in patients with TB and HIV co-infection, compared 
to TB patients without HIV, despite the reduction in CD4+ T cells in HIV patients.7 
Adjuvant system tuberculosis vaccine administered to HIV+ and HIV-  individuals, 
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triggered and maintained both humoral and cellular immune systems for up to three years 
after two doses regardless of antiretroviral therapy (ART), with the highest results seen in 
ART+ patients.8 Furthermore, vaccination against tuberculosis has also shown to enhance 
CD4+ memory T cells for over one year post-vaccination.9 This increase in memory CD4+ 
T cells could replenish depleted CD4+ cells in HIV patients and boost the adaptive immune 
response. Wu et al. also isolated broadly neutralizing antibodies (Abs) against HIV-1 in 
HIV patients, which gives insight into the possibility of HIV vaccines.10  
Previous research has highlighted a promising approach to HIV therapeutics using 
the adaptive immune system, instead of targeting the replication cycle of HIV. 
Understanding the immune response elicited by TB and HIV individually and in TB and 
HIV co-infections will be critical in this approach. However, there is not much known 
about the humoral response mechanism in TB and HIV co-infections. Most of the research 
conducted have discussed the humoral response regarding CD4+ T cells, and Th1 cells in 
co-infected patients and HIV patients vaccinated against TB. This thesis research delves 
into how tuberculosis co-infection in HIV affects, specifically, the B cell immune response. 
We will also investigate this B cell response by focusing on the role the B-cell activating 
factor (BAFF) system molecules play in TB and HIV co-infections.  
The BAFF system molecules consist of 3 receptors; B-cell activating factor receptor 
(BAFF R), transmembrane activator and calcium-modulator and cytophilin ligand 
interactor (TACI), and B-cell maturation antigen (BCMA). The BAFF system molecules 
include 2 ligands, BAFF and A proliferation-inducing ligand (APRIL).11 The BAFF system 
molecules connect the innate and adaptive immune responses.12 BAFF and APRIL are 
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members of the Tumor Necrosis Factor (TNF) ligand superfamily. The members of the 
TNF family control cell growth, differentiation, and death.13 BAFF plays a crucial role in 
the survival of transitional and mature B cells. When BAFF is overexpressed, it causes the 
B cell compartment to expand and results in autoimmunity in mice and human patients.14 
Membrane-bound BAFF and APRIL are cleaved by furin convertase into their soluble 
form. Soluble BAFF is cleaved into either a homotrimer or an oligomer. Soluble 
homotrimeric BAFF can bind only BAFFR, while the soluble oligomeric BAFF can bind 
all the 3 receptors BAFFR, TACI, and BCMA. Soluble APRIL exists as a homotrimer and 
binds to TACI and BCMA only if bound to heparan sulfate proteoglycan (HSPG). Soluble 
APRIL cannot bind BAFFR (Figure 3). 11 BAFF and APRIL, although they share similar 
receptors, have their unique role in B cell responses.14  
The BAFFR is responsible for B cell survival and is expressed on most mature B 
cells beyond pre-B cells; however, it is not expressed on plasma cells. Further, its 
expression is more pronounced in follicular and germinal center B cells. TACI is involved 
in generating plasma cells and isotype switching and is expressed mostly on marginal zone 
B cells. Research also shows that TLR activation increases the expression of TACI on B 
cells to promote plasma cell generation, immunoglobulin secretion, and increased 
expression of TACI, which in turn increases B cell sensitivity to BAFF and APRIL. TACI 
and BCMA are also expressed on plasma cells and memory B cells. BCMA also facilities 
antigen presentation by B cells.11 Previous research conducted shows that the BAFF system 
molecules could potentially provide insight on how autoreactive B cells develop, as these 
 
6 
molecules play a crucial role in the survival of transitional type 2 B cells, B cell responses, 
growth, and clearance.11  
Although B cells are not the direct target of the HIV-1 virus, elevated levels of 
BAFF in the serum of HIV-1–infected individuals have been considered a trigger for B cell 
activation.15  Previous research suggests that BAFF significantly contributes to myriad 
HIV-1-associated B cell dysfunctions, including hypergammaglobulinemia, nonspecific B 
cell activation, class switching, increased cell turnover, tolerance breakage, and a 
compromised ability to generate and maintain memory15 This B cell activation could be 
possible through innate immune system cells like macrophages, which are targets for HIV 
and can produce BAFF and APRIL ligands. Macrophages are phagocytes, and antigen-
presenting cells (APC), that are found in almost every tissue and serve as a reservoir for 
HIV.16 Macrophages in human peripheral blood that are cultured in vitro with specific 
cytokines can support HIV‐1 infections because they express the chemokine receptor 
CCR5, which interacts with glycolipids on the HIV envelope.17 Research shows that 
compared to CD4+ T cells, macrophages are more resistant to the cytopathic effects of HIV 
infection. They can also better contain HIV than CD4+ T cells.16 This is because HIV-
infected CD4 T cells secret more viral particles and accumulate less of them.  
Additionally, macrophages have this advantage because they can store viral 
particles in their large vacuoles.17 Other research papers also describe that HIV buds off 
into intracellular multivesicular bodies in macrophages. 16 Macrophages are great long-
term reservoirs of HIV particles and facilitate HIV replication, thereby contributing to the 
spread of the virus in the host.15 In HIV-1 infected MDM cultures, the production, and 
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secretion of BAFF mRNA and protein expression, respectively, are induced. An 
upregulation of BAFF was observed in the HIV cultures, which also positively correlated 
with increased HIV-1 replication.15   
The phenotype of macrophages also influences HIV-1–mediated BAFF production. 
For example, macrophages treated with M-CSF have an M2-like phenotype and, compared 
to M1 macrophages, produce a different BAFF level in response to HIV. This may be due 
to the different capabilities of sustaining viral particles and supporting viral replication.15 
The levels of BAFF produced by macrophages depend not only on macrophage phenotype 
but also on tissue-specific immune-modulating cytokines, chemokines, and microbial 
products.15 Previous research comparing the M1 and M2 macrophage phenotypes shows 
that HIV- negative M1 MDMs produced higher levels of BAFF in comparison to HIV- 
negative M2 or M0 MDMs. On the other hand, when M1 MDMs are infected with HIV-1, 
the macrophages support HIV-1 replication less, thereby reducing HIV-1–mediated BAFF 
upregulation. In M2 MDMs, however, HIV-1 infection results in increased support in viral 
replication and also increases sustainment of viral particles.15 
Furthermore, macrophages contribute to M .tuberculosis pathogenesis and HIV 
infection. They are reservoirs of both M. tuberculosis and HIV and are also the primary 
effector cells against M. tuberculosis.18 In order to understand their combined effect, 
previous research conducted has explored the effect of HIV and M. tuberculosis co-
infection in macrophages. They have particularly investigated macrophage gene 
expressions in response to HIV and M. tuberculosis co-infection.18 Active TB and HIV-1-
coinfection showed an increase in soluble markers of monocyte activation, which are 
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CD14, IL-6, and IL-8.2 Thus, we propose that this would be the same for BAFF and APRIL. 
This is because research shows significant increases in transcription of macrophage 
chemokines, cytokines, and their receptors in tuberculosis and HIV/TB culture 
supernatants.18 However, this change in HIV infection only was not as significant. This 
shows that the effects M. tuberculosis has on transcription, gene expression, and immune 
activation superseded the effects of HIV and M. tuberculosis co-infected macrophages.18,2 
Different strains of M. tuberculosis also vary in their ability to induce HIV-1 replication 
and cause gene expression changes.2 
Research suggests that when macrophages are activated in TB and HIV co-
infections, TLR expression and function can be increased, which in turn affects the 
inflammatory response.19 They proposed that TLRs could contribute to promoting HIV-1 
replication. .19 They observed that MDMs and PBMCs infected with HIV-1 compared to 
HIV-negative culture, when their TLRs were stimulated, increased TLR expression and 
production of proinflammatory cytokines. When the HIV MDMs were infected with LPS 
and LP, both TLR agonists, their results showed an increase in HIV-1 replication and TLR 
expression. LPS, a TLR4 agonist, has been shown to induce BAFF and APRIL in antigen-
presenting cells.11 Although LM is a TLR2 agonist, prior research with VSVg-NL43 
demonstrated that HIV-infected MDMs stimulated with Pam2CSK4, a TLR2 agonist, 
increases TLR4 expression as well. However, this didn’t yield the same results vice versa.19  
Therefore, we aim to stimulate and increase HIV-1 replication in MDMs using the 
TB antigen LM, a TLR2 agonist, to represent HIV/TB co-infection in vitro. From there, 
we will measure the amount of BAFF and APRIL produced in these MDMs and their 
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effects on the survival of B cells (Figure 4). We will also compare these results to HIV-
infected MDM cultures, LM cultures, and uninfected MDM cultures. We hypothesize that 
LM increases the survival of B-cells through the BAFF system molecules in HIV patients. 
The results of our research will allow us to observe the role TB plays in the B cell humoral 
immune response in HIV-1 patients. Our results will give us critical insight into 
understanding the mechanism responsible for this and  provide background research 
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Figure 1. The structure of HIV. HIV-1 has an envelope made up of the glycoprotein 
Gp160. It also has a capsid protein that contains viral genomic RNA and the replication 
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Figure 2. The HIV replication cycle. This diagram illustrates the glycoprotein-
facilitated entry of HIV into the host’s cell, the action of HIV enzymes: reverse 
transcriptase, integrase, and proteases, and how the newly formed viral product buds of 










Figure 3. The BAFF system molecules. The BAFF system molecules consist of three 
receptors; BAFF R, TACI, and BCMA and two ligands, BAFF and APRIL. Membrane-
bound BAFF and APRIL are cleaved by furin convertase into their soluble form. Soluble 
BAFF is cleaved into either a homotrimer or an oligomer. Soluble homotrimeric BAFF 
binds BAFFR, while the soluble oligomeric BAFF binds all three receptors. Soluble 
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Figure 4. A framework of the relationship between TB and HIV infected MDMs, 
BAFF and APRIL Ligands and B cells. This diagram shows that the BAFF system 
ligands, BAFF and APRIL, that are produced from MDMs, under four different treatment 














Previous research shows the involvement of the BAFF system molecules in 
pathogenic infections such as HIV and Tuberculosis.11,15 In HIV-infected cells, there is an 
increased expression of BAFF and APRIL, and an association of these ligands with 
hypergammaglobulinemia. Similarly, in TB patients, they found increased plasma levels 
of BAFF and APRIL, which correlated with disease severity.11 Studies from our lab 
showed that active TB correlates with elevated levels of BAFF and APRIL in HIV-infected 
volunteers. We also found that active TB is associated with plasma neutralizing activity 
against 12 tier 2 or 3 HIV-1 isolates.  
The project aims to investigate the role the BAFF system molecules play in the 
survival of B cell growing in MDM media from MDMs infected with HIV, TB, or both. In 
this paper, we plan to measure the amount of BAFF and APRIL produced in HIV, LM, and 
HIV/LM infected MDMs. We will also compare B cell survival in the presence of the 
ligands BAFF and APRIL from these HIV, LM, and HIV/LM MDM media. Our findings 
will provide preliminary results that will aid in understanding the importance of the BAFF 
system molecules in humoral immunity in patients with HIV and tuberculosis co-infection. 
Furthermore, since LM is a TLR agonist and is considered a vaccine adjuvant, our findings 
will provide a good foundation for further research on the B cell response mechanism in 






Our methods section consists of the CD14+ cell isolation and MDM culture 
experiments conducted and subsequent planned experiments that are yet to be carried out.  
 
PBMC Isolation  
Human blood without plasma was obtained from healthy patient volunteers and 
Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll density gradient 
centrifugation. 20 mL Histopaque (Ficoll) was pipetted into four different 50 mL tubes 
and 12.5 mL of blood was layered gently into each tube with Ficoll to avoiding mixing. 
The tubes were centrifuged for 30 minutes at 1500 RPM and room temperature, with zero 
breaks, and the PBMC Layer was carefully removed with a pipette. After that, the 
PBMCs were washed with 50 mL PBS twice, each time centrifuging for 10mins at 
1500RPM and with maximum break. The cells in the four tubes were combined on the 
second wash, and the PBMCs were resuspended in PBS, filling the tube up to 50 mL. The 
cells were counted on a hemocytometer, and 200 × 106cells/ 2 mL was the final amount 
of cells used for the CD14+ isolation experiment.  
 
CD14+ Cell Isolation  
Human CD14+ monocytes were then isolated through magnetic separation from 
the PBMCs using the Stemcell technologies EasySepTM CD14 Positive Selection kit II. 
200 × 106cells/ 2 mL were placed in a 5 mL (12 x 75 mm) polystyrene round-bottom 
tube, 200 µL of selection cocktail was added to the sample, mixed and incubated at room 
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temperature for 10minutes. RapidSphereTM was vortexed for 30 seconds, and 200 µL of 
RapidSphereTM was added to the sample. The sample was mixed and incubated at room 
temperature for 3 minutes. After, 100 µL of the isolation medium ( PBS containing 2% 
FBS with 1 mM EDTA) was added to a final sample volume of 2.5 mL. The tube was 
placed into a magnet and incubated at room temperature for 10 minutes, and the 
supernatants were carefully discarded using a pipette. The sample leftover in the tube was 
resuspended in 2.5 mL of isolated medium and incubated at room temperature for 
10minutes. After 10 minutes, the supernatant was discarded as described before, and the 
washing step was repeated again. At the end of the experiment, there were a total of three 
10 minute separations. The cells were counted on a hemocytometer .  
 
MDM Culture  
The isolated CD14+ monocytes were differentiated into macrophages by 
resuspending monocytes in macrophage-derived monocytes (MDM) media. The media 
contained 45 mL RPMI, 5 mL of 10% heat-inactivated human AB serum (and 500𝜇l 
Pen/Strep filtered through a 0.45 𝜇m filter. 20 ng/mL of human M-CSF was added right 
before the MDMs were cultured. 250 × 103cells/ 0.5 mL of the MDMs were seeded per 
well on a 24 well plate, and cultured for 5 days with no media change in a 37°C in a 
humidified 5% CO2 atmosphere. On day 5, the media in each well was replaced with 
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Figure 5. CD14+ Cell Isolation and MDM Culture from peripheral blood. PBMCs 
were isolated from whole blood, and magnetic separation was carried out to positive 
select of CD14+ monocytes. The isolated monocytes were differentiated into MDMs and 







HIV Infection of MDMs 
On day 7, the MDMs will be infected by adding double pseudotyped VSVg-NL43 
virus to the MDMs at a volumetric ratio of 1:1000 (virus stock to serum-free cell culture 
media). After incubating for 4 hours, the infected MDMs will be washed with Phosphate-
buffered saline (PBS). Fresh MDM differentiation media will be added, and the infected 
MDMs will be cultured for at most 48 hours. The conditioned media from the wells will 
be centrifuged at 5000 RPM for 10 minutes, and the supernatant will be filtered through a 
0.22μm filter and stored at -80°C. 
 
LM Stimulation of MDMs 
MDMs will be cultured in a 24 well plate with MDM media containing three 
different concentrations (25μg/ mL, 50μg/ mL, and 75μg/ mL) of NR-14850, purified 
lipomannan (LM), obtained from the cell wall of gamma-irradiated Mycobacterium 
tuberculosis strain H37Rv. The MDMs with NR-14850 will be cultured for 24 hours at 
37 °C . The conditioned media from the wells will be centrifuged at 5000 RPM for 10 
minutes and the supernatant will be filtered through a 0.22μm filter and stored at -80°C.21,22  
 
LM Stimulation and HIV Infection of MDMs 
After 24 hours, the HIV-infected MDMs will be stimulated with NR-14850, 
purified lipomannan (LM), obtained from the cell wall of gamma-irradiated 
Mycobacterium tuberculosis strain H37Rv at the same concentrations described before. 
The HIV/LM infected MDMs will be cultured for another 24 hours. The conditioned media 
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from the wells will be centrifuged at 5000 RPM for 10 minutes, and the supernatant will 
be filtered through a 0.22 mm filter and stored at -80°C. 
 
B cell isolation  
B cells will be negatively selected from whole blood by magnetic separation using 
the MACSprep™ HLA B Cell Isolation Kit.23 The isolation protocol requires that the B 
cell isolation cocktail, a lyophilized pellet, is reconstituted by adding 1.25 mL of Buffer 
A and mixing gently with a pipette 3-4 times. For 1 mL of blood, 0.25mL of reconstituted 
pellet will be added to 0.25 mL of Buffer B and mixed gently. The freshly prepared 
cocktail will be added to 1 mL of whole blood sample in a 5 mL tube for magnetic 
labeling. The tube will be inverted gently three timed while tightly closed, and will be 
incubated for 5 minutes at room temperature using a tube rotator. The sample will be 
transferred into a 2 mL tube, and the open tube will be placed in a magnetic field. The 
supernatants containing the unlabeled target lymphocytes will be carefully collected with 
a pipette without disturbing the pelleted erythrocyte pellet. An aliquot of the supernatant 
will be taken for cell counting. 
 
B Culture and Stimulation 
The isolated B cells will be plated in a 24 well plate with approximately 200 B-
cells per well in 500 µLR5 medium, which contains RPMI-1640, 5% human serum, 55 µM 
2-mercaptoethanol, 2 mM L-glutamine, 100 U/mL penicillin,100 µg/mL streptomycin, 10 
mM HEPES, 1 mM sodium pyruvate and 1% MEM nonessential amino acids and 
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supplemented with 10 ng/mL IL-4.24 The B cells will be cultured using 1:1, 1:2, 1:4, 1:8, 
1:12 dilutions of the filtered conditioned media from the HIV and LM MDMs culture, and 
the R5 medium for 8 days, refreshing half the media on days 4 and 6.  
 
Counting Cells and B cell Growth Curve  
The number of B cells cultured will be counted every two days for at least a week 
using a KOVA glasstic slide with 10 counting chambers and at a 1:10 dilution of trypan 
blue dye and B cells. Each chamber is divided into a 9 x 9 grid, where each grid has the 
size 3 mm × 3 mm × 0.1 mm. 10μL of the dye and B-cell dilution will be pipetted into the 
chamber and placed under the microscope.25 The viable unstained cells will be counted in 















                    Created with BioRender.com 
Figure 6. A KOVA glasstic slide (a) with 10 chambers and a 9 x 9 grid in each 
chamber (b). Unstained viable cells were counted in three 1 mm x 1 mm square, 
diagonally, out of nine and divided by three to find the average number of cells present in 







RNA Isolation  
48 hours post-infection, the MDMs from each condition will be scraped from the 
plate. The cells will be pelleted by centrifuging for 2 minutes at 5000 rpm. After that, the 
PBS will be removed and resuspended in 250 µL of Lysis Buffer. The lysis buffer 
contains 1 µL of 1000x beta-mercaptoethanol per 1mL of Qiagen RLT Lysis Buffer. The 
resuspended cells will be added to a Qiagen QIA shredder column and centrifuged for 3 
minutes at top speed to homogenized the cells. The homogenized sample will be added to 
the DNA spin column and Centrifuged for 30 seconds at 8000 rpm. The DNA spin 
column will be discarded, and the elute will be saved for RNA isolation.   
250 µL of 70% ethanol will be added to the elute and mixed carefully. The sample 
will be added to the RNA spin column and Centrifuged for 30 seconds at 8000 rpm. The 
elute will be discarded, and 350 µL of RW1 buffer will be added to the RNA spin 
column. The tube will be Centrifuged for 30 seconds at 8000 RPM, and the elute will be 
discarded. 80 µL of DNase treatment will be added per RNA spin column and incubated 
at room temperature for 10 minutes. The DNase treatment includes 10 µL of DNase and 
70 µL Buffer RDD. After 10 minutes, 350 µL of Buffer RW1 will be added to the 
column, and the column will be centrifuged for 30 seconds at 8000 RPM. The solution in 
the collection tube will be discarded. 500 µL of Buffer RPE will be added to the column 
and centrifuge for 30 seconds at 8000 RPM, and the eluted solution will be discarded. 
This step will be repeated twice. After, the RNA spin column will be transferred to a new 
collection tube and centrifuged for 1 minute at 8000 RPM to dry the column. The RNA 
spin column will be transferred again into a 1.5 mL microcentrifuge tube for elution of 
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the RNA. This will involve adding 40 µL of RNase free water to the column and 
incubating for 5 minutes. After, the columns will be centrifuged for 1 minute at 8000 
RPM and immediately discarded. The RNA will be transferred to ice, and the 
concentration will be measured using the NanoDrop Spectrophotometer.  
 
cDNA Synthesis using SuperScript Reverse Transcriptase  
RNA isolated from the treated MDMs and the control will be converted to cDNA 
in two reactions, for both the reverse transcriptase samples and the no reverse 
transcriptase reaction samples. 
 Reaction one will require Random Primers (Promega 50 µg/mL), 10 mM dNTP, 
and 500-100ng of RNA diluted with DEPC water to reach a desired concentration (Table 
1). The samples will be placed in a thermocycler at 65°C for 5 min, and the condensate 
will be spun down and stored. 
 
Table 1. RT and NO RT sample reaction 1. The final volume of RT and No RT 
samples will be measured according to the volumes and concentrations shown in the 
Table.  
 RT sample No RT sample 
RNA 500-1000ng 9 µL 3 µL 
Random Primers (Promega 50ug/mL) 2 µL 0.67 µL 
10 mM dNTP mix 1 µL 0.33 µL 
TOTAL VOLUME 12 µL 4 µL 
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The second reaction will require 5X 1st strand buffer (Invitrogen), 0.1M DTT 
(Invitrogen), 40U/µL Rnase-out (Invitrogen), SuperScript RT (Invitrogen) and, DEPC 
water (Table 2).   
 
Table 2. RT and NO RT sample reaction 2. The final volume of RT and No RT 
samples will be measured according to the volumes and concentrations shown in the 
Table. 
 RT sample No RT sample 
5X 1st strand buffer (Invitrogen) 4 µL 1.33 µL 
0.1M DTT (Invitrogen) 2 µL 0.67 µL 
40 U/µL Rnase-out (Invitrogen) 0.1 µL 0.03 µL 
SuperScript RT (Invitrogen) 0.5 µL NONE 
DEPC water 1.4 µL 0.63 µL 
TOTAL VOLUME 8 µL 2.67 µL 
 
The product from reactions 1 and 2 will be mixed and incubated at 42 °C for 50 
minutes and at 70° C for 15 minutes using a thermocycler. Approximately 40 µL of 






Standard qPCR using SYBR Green 
A standard qPCR using SYBR Green will be carried out to measure BAFF and 
APRIL gene expression from MDMs that are treated with HIV, LM, and HIV/LM. Using 
GAPDH as a housekeeping gene, the Ct values of the different MDM media will be 
compared.26 Three master mixes containing the target of interests BAFF, APRIL, and 
GAPDH will be made according to the Sagar lab protocol (Table 3) and kept on ice. 
Equal amounts of cDNA at a concentration of 100 ng will be added to 15 µL of each 
master mix per well resulting in 25 µL of sample per well (Table 4). The qPCR will be 
run using the conditions described in Table 5.  
 
Table 3. Master Mix for qPCR reaction. The final volume of the master mixes for each 
target will be measured according to the volumes and concentrations shown in the Table. 





2X 12.5 1X 
Primer Forward 10 µM 0.75 300 nM 
Primer Reverse 10 µM 0.75 300 nM 
SYBR Green 
1 X 1 - 
Water - Variable - 






Table 4. 96 well plate for 8 samples. Plate set up for 8 different MDM culture conditions 
to measure three target genes, BAFF, APRIL, and GAPDH, for RT and NO RT samples.  
 1 2 3 4 5 6 7 8 9 10 11 12 
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 Reagent Temperature Time Cycles 
Hold Stage Enzyme activation 95C 15 minutes 1 
PCR Stage DNA denaturation 95C 15 seconds 40 
Annealing/Elongation *60C 60 seconds 
Fluorescence capture - - 
Melt Curve 
Stage 
DNA denaturation 95C 15 seconds continuous 
Annealing 60C 60 seconds 
Dissociation and 
fluorescence capture 





CD14+ Cell Isolation and MDM Culture  
 
324 unstained and viable cells were counted using the glass slide. Since only three 
1mm x 1mm squares were counted diagonally, as shown by the green line in Figure 6, we 
calculated the estimated number of PBMCs isolated, factoring dilutions and the number 
of grids counted using equation 1. From our 50 mL tube, 1080 × 106 PBMCs were 
isolated. We aliquoted 9.25mL from the 50ml tube and resuspended PBMCs to reach a 
concentration of 100 × 106 cells/ ml.  2mL of the PBMCs were used for CD14+ 
selection. On day 1, the Macrophages appeared aggregated under the microscope slides. 
There were also remnants of the beads visible under the slide as there were brown 
particles floating amongst the CD14+ isolated cells. Further, the cells did not adhere 
properly to the wells, as a result, only a few MDMs were retained. On day 5-7, the 
morphology of the few adherent cells begun to change subtly, from a round spherical 
shape to an irregular shape with spikes. After day 7, the cells begun to shrink and die. 
 In a repeated experiment, we successfully differentiated the MDMs. On day 1, 
the isolated CD14+ cells (Figure 7) were floating under the microscope. They did not 
form aggregates and neither did they have remnants of the beads visible under the slide. 
On day 2 (Figure 7), the morphology of the cells had begun to change from round shaped 
cells to irregular and spiked shaped MDMs signifying the early stages of differentiation. 
However, were not fully adhered to the plate. On day 8 (Figure 7), the MDMs were fully 
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differentiated, with more pronounced morphological changes compared to day 2. The 
MDMs had also fully adhered to the plate.  
 
LM Stimulation and HIV Infection of MDMs 
Previous research done in our lab investigated the enhanced neutralizing activity 
of antibodies induced by Tb infections. The experiment was carried out using HIV-1 
infected individuals with active TB before TB treatment. The levels of cytokines and 
ligands, including BAFF and APRIL, in the plasma, was measured (Figure 8). The results 
of the experiment showed higher levels of BAFF and APRIL in pretreatment active TB 
and HIV co-infected individuals in comparison to pretreatment HIV-1 infected 
individuals only. We expect to obtain similar results from our HIV-positive MDM 
cultures that are co-infected with lipomannan (LM) of Mycobacterium tuberculosis. We 
anticipate lower Ct values from our RT- PCR experiment. Ct values are inversely 
proportional to mRNA levels.26 
 
HIV Infection of MDMs 
The same experiment also measured the levels of BAFF and APRIL in HIV-1 
infected individuals without active TB. The levels of BAFF and APRIL measured in the 
plasma, showed lower concentrations of BAFF and APRIL in pretreatment HIV-1 
infected individuals as compared to pretreatment active TB and HIV co-infected 
individuals (Figure 8). We expect to obtain similar results from our HIV-positive MDM 
cultures. We expect higher Ct values and lower BAFF and APRIL mRNA levels in HIV-




LM Stimulation of MDMs 
From the previous experiment conducted in our lab, we expect that LM exposed 
individuals in non-HIV-1 infected patients will have similar levels of BAFF and APRIL 
compared to HIV-1 infected individuals with LM, but higher levels of BAFF and APRIL 
compared to HIV-1 infected individuals without LM. We expect the RT-PCR to show 
lower Ct values for LM and LM/HIV infected MDMs.  
 
RNA Isolation  
 The result obtained from the 1 × 106 MDMs per well on day 7 was 2.3ng/μl, 
which is a low mRNA yield. For successfully isolated and differentiated MDMs, the 
expected results for the same number of cells should be 400-600ng/μl. 
 
B cell Culture and Stimulation  
We expected an approximately 98.3% yield of B cells and a purity of about 96.1% 
based on previous flow cytometry research done by Summerauer et al, after using the 
MACSprep™ HLA B Cell Isolation Kit and a whole blood volume of 4.5mL.27 Their 
results also show that 1.3–2.7 ml blood from healthy individuals, produced 136,700 B 
cells/ml. We expect to obtain at least 30,000 B cells needed for our experiment using 
1mL of whole blood.27 We expect to see morphological changes in B cell cultures as they 




Counting Cells and B cell Growth Curve  
 
   We expect the B-cell to have the features of a typical growth curve with the lag, 
logarithmic, stationary, and death phases. Previous experiments conducted on the kinetics 
of mature naive B -cell proliferation by Su et al shows that the number of B-cells will 
decrease as the days progress. Their results are from 1 × 103 B cell plated in each well in 
a 6- well plate. On days 4, 6, and 8, there were 1 × 104, 2.5 × 103, and 1 × 103 B cells 
per well. Therefore, we expect the highest number of cells on day 4, followed by a 
decrease on the subsequent days after.28 We also expect the survival of B-cells to 
correlate with BAFF and APRIL concentrations. We expect to see on day 4, higher B 
cells counts in all LM and HIV/LM MDM cultures because they have been shown to 








3 (1mm × 1mm grid)
= 108 
108 ×  10 (dilution factor) = 1080  




Equation 1. Equation used to calculate the number of PMBCs isolated from whole 
blood.  324 cells were counted in three 1mm x 1mm square, diagonally, out of nine and 













Figure 7. Light microscope images of MDMs on day 1, 2 and 8. CD14+ monocytes 
that were isolated in the repeated experiments, were plated in a 24 well plate in MDM 
media and cultured and differentiated for 8 days. On day 2, the cells begun to 
differentiate as shown by the change in the morphology of the cells. On day 8, the MDMs 
were fully differentiated.   
Day 1 






Figure 8. BAFF and APRIL concentration in the plasma of HIV and HIV/TB 
infected individuals. The concentration of APRIL and BAFF is higher in HIV-1/TB 
































































































































































































































































































































Since we used M-CSF in the MDM media, we expected to obtain MDMs that are 
predominantly polarized to form MDMs with M1 phenotypes, which are also known as 
classically activated macrophages.29 M2 macrophages, also known as alternatively 
activated macrophages, are anti-inflammatory and promote wound healing, however, M1 
macrophages are pro-inflammatory and driven by tissue injury.30 M1-like polarized 
macrophages exhibit a high level of phagocytic activity and, therefore, are likely to 
produce more cytokines and ligands during an innate immune response 30. Our initial 
results for the MDM differentiation was unsuccessful because not only were there few 
MDMs that were adherent on day 5-6 after seeding, but also because the MDMs looked 
unhealthy and died shortly after. Our results indicate that there was an experimental error 
made in the CD14+ isolation step and the differentiation step. The microscopy images of 
the MDMs culture, as early as day two, showed aggregated cells that were contaminated 
with beads from the isolation experiment. In our repeated experiment, we used the CD14+ 
isolation media which contained EDTA. We also carefully poured out the supernatant 
while the tube was still in the magnet, and washed the beads with the isolation media. On 
day 8 (Figure 7), our MDMs successfully differentiated because they were not aggregated 
and were not contaminated with the magnetic beads. Future experiments can include 
using real time-PCR to detect the type of MDM phenotype present. M1 macrophages 
markers are CD80, and M2 macrophages markers are CD200R.29 
Macrophages are great reservoirs for HIV, and M1 macrophages have been shown 
to  increase phagocytic activity, thus, for our experiment, we expect an increase in 
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transcription of BAFF and APRIL in the HIV-1 infected MDM cultures compared to the 
HIV-1 negative and LM negative controls.15 Based on the experiments carried out 
previously in our lab, the levels of BAFF and APRIL measured in the plasma showed 
lower concentrations of BAFF and APRIL in pretreatment HIV-1 infected individuals, 
compared to pretreatment active TB and HIV co-infected individuals (Figure 8). 
Similarly, we expect the results for our experiments to show higher levels of BAFF and 
APRIL mRNA, which corresponds to lower Ct values in HIV positive MDM cultures co-
infected with LM in comparison to HIV-1 infected patients only. This is  because 
previous research has shown that transcription and gene expression of macrophage 
cytokines, chemokines, and their receptors increased significantly in HIV and TB co-
infection culture supernatants.18 We also expect to obtain similar results for our HIV-
positive MDM cultures co-infected with LM and our LM only infected cultures. This is 
because, experiments comparing the gene expression and transcription of cytokines in 
HIV, TB, and HIV/TB co-infection cultures, show that HIV-1 infection causes an 
insignificant change in gene expression and transcription of macrophage cytokines, 
chemokines, and their receptors as compared to TB. These experiments further highlight 
the effect M. tuberculosis infection has on gene expression, transcription. The immune 
activation induced by TB superseded the effects of HIV-1 in HIV/TB co-infected 
macrophages.18,2 Additionally, the ability of M. tuberculosis to induce HIV-1 replication 
and cause gene expression changes to differ, depending on the strain of M. tuberculosis. 
We, therefore, expect LM, which is obtained from the cell wall of the irradiated M. 
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tuberculosis strain, H37Rv, to have a milder response compared to the whole live strain 
of M. tuberculosis.2 
The results we expect to see based on previous research conducted in our labs and 
in other places will show that the timeline of infection of the MDMs, impacts the results 
of the experiment. Previous research shows that macrophages that were infected with a 
purified virus for four days resulted in a higher percentage of infected cells, which 
doubled on day five. However, our MDM cultures were infected with HIV for a 
maximum of 48 hours in order to avoid high levels of toxicity in the conditioned media 
which was going to be used in activating the B-cells .18 As a result, we expect a lower 
percentage of HIV-infected cells, which might affect the production of BAFF and 
APRIL. We propose that the effect this will have, especially in our HIV/LM cultures, will 
be insignificant. This is because the MDM response to M. tuberculosis infection 
supersedes the HIV response, and previous research conducted shows that M. 
tuberculosis infection for twelve hours is sufficient to yield a good macrophage response. 
Our experiments included LM infections at three different concentrations for double the 
time. We doubled the time for our LM infection in our experiment because LM is a 
component of the cell wall of the attenuated M. tuberculosis virus used in their research. 
A limitation of our experiment is that 48 hours post-infection, the HIV, LM, and HIV/LM 
co-infected MDM cultures were lysed for RNA isolation and subsequent cDNA and RT 
PCR experiments. In order to have accurate results on BAFF and APRIL mRNA 
concentrations in the different MDM cultures, RNA can be lysed at shorter time intervals 
during infections, for example, 12 hours, 24hrs and 48hrs post-infection, to observe if 
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there are any relevant changes in the RNA concentration or yield, and to find the highest 
mRNA concentration.  
We expect our isolated B-cells to have the features of a typical growth curve with 
the lag, exponential, stationary, and death phases. In previous B cell culture experiments 
conducted, the B cell count on day 4, resulted in the highest number of B cells.24 From 
this experiment, we expect the B cells to reach their stationary phase, the phase with the 
highest number of B cells, on day 4. In addition, we predict higher B cells counts in LM 
and HIV/LM MDM cultures. This is because, as shown by previous experiments 
conducted in our lab, TB increases BAFF and APRIL concentrations, and BAFF 
promotes survival in transitional B cells.31   
Transitional stage 1 (T1) B cells are produced in the bone marrow and are present 
in peripheral blood. In the spleen, T1 B cells differentiate into transitional stage 2 (T2) B 
cells and into the mature follicular and marginal zone B cells.32,11 The B cells in our 
experiment were isolated from whole blood. These naïve and mature CD19+ B cells 
found in the blood periphery only express BAFF receptors.11 TACI is expressed in B 
cells located in the spleen and peritoneal cavity, and BMCA is expressed in plasmablast, 
plasma cells, and memory cells. Thus, we expect  B cell survival, shown by an increase in 
B cell count in the LM and HIV/LM co- infection cultures, to be attributed to BAFF-R 
and BAFF only since APRIL does not bind to BAFF-R.11 Furthermore, among the three 
BAFF receptors, BAFF‐R plays a vital role in transducing B lymphocyte survival signals. 
BAFF, when it interacts with BAFF-R plays a vital role in the maturation of B cells, 
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specifically, in the transition of T1 B cells to T2 B cells and plasma cell survival.20 BAFF 
also increases immunoglobin secretion and facilitates isotype switching. 20 
Other studies also show that BAFF contributes to the survival of T2 B cells, but 
not T1 B cells, and also does not contribute to the transition of T1 B cells to T2 B-cells. 
As a result, if our results show, contrary to our expectation, no increase in the survival of 
B cells in the media containing LM, then the results suggest that BAFF does not 
contribute to T1 B cell survival, or drive T1 B cells to differentiate into its T2 stage.31   
The proposed mechanism by which BAFF through BAFF-R increases B cell 
survival was investigated in previous research. The findings of this research support the 
idea that BAFF increases B cell survival by inducing anti-apoptotic factors. In their 
experiment, when B-cells were exposed to BAFF for an extended period of time, there was 
an increase in expression of the surface marker B220 and the anti-apoptotic factor, Bcl-2, 
in early transitional B cell cultures.31 Their results showed that BAFF through NF-κB 
factors increasing B cell survival from their T1 stage until they are fully differentiatied.31 
Additionally, BAFFR signaling mediates B cell survival by preventing TRAF2/TRAF3 
from inhibiting the alternative NF-κB pathway .33  
LM may be present in the conditioned media since its size may be smaller than the 
0.22µm filter. If this is the case, the effect of LM on the survival of B-cell will be 
insignificant, because, unlike LPS, a TLR4 agonist, which upregulates BAFF‐R and TACI 




In future studies, the effect of BAFF on B-cell will be better studied from its T2 
stage when the B cell has all its BAFF and APRIL receptors. Previous research, using a 
tonsil organoid, modeled the human adaptive system and demonstrated the B cell 
maturation process  and its environment in vitro. Important components of the adaptive 
immune system, such as the   germinal center was replicated. Observation of processes, 
such as the production of antigen-specific antibodies and somatic hypermutation was also 
made possible.35 In the same way, the various stages of B cells can be captured in a 
spleen organoid. This will paint a clearer picture of how BAFF and APRIL increase B 
cell survival as compared to experiments done on mature and naïve T1 B-cells in the 
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